Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CEACAM5
REST API REST API
Homo sapiens
CEACAM5 is differentially expressed in 175 experiments: 122 organism parts: trachea, tonsil, ... (120 more);, 68 disease states: normal, lung adenocarcinoma, ... (66 more);, 43 cell types 333 cell lines 17 compound treatments and 55 other conditions.
Synonyms CD66e, CEA
InterPro Term Ig_V-set, Ig_sub, Immunoglobulin, Ig-like, Ig_sub2, Ig_I-set
Gene Ontology Term plasma membrane, protein binding, anchored to membrane, basolateral plasma membrane, integral to plasma membrane
UniProt Accession Q7KZ28, P06731, E7ESE8
Search EB-eye ENSG00000105388
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-1880, E-GEOD-22639, E-GEOD-19639, ... (22 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
SNU16
2
E-MTAB-37, E-GEOD-15460
327 more value(s).


Cell type

studied in E-GEOD-18811, E-GEOD-22529, E-AFMX-5, E-MEXP-1251, E-MTAB-24, ... (21 experiments)

Factor Value U/D Experiments
macrophage
1
E-GEOD-3982
mesothelial cells
1
E-GEOD-21750
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
purified B cells from peripheral blood from donors 60 years of age and older
1
E-GEOD-22529
purified CLL B cells from peripheral blood
1
E-GEOD-22529
CD133+ prostate epithelial cell
1
E-MEXP-993
37 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-22529, E-TABM-15, E-MEXP-2280, E-GEOD-9692, ... (31 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
1
3
E-MTAB-62, E-GEOD-2514, E-MEXP-231, E-MTAB-37
colon carcinoma
2
E-GEOD-3726, E-MTAB-37
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
hepatitis c
1
E-MTAB-62
extranodal NK/T-cell lymphoma
1
E-GEOD-19067
myeloma
1
E-MTAB-372
62 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-MEXP-2218, E-GEOD-412, ... (12 experiments)

Factor Value U/D Experiments
actinomycin D
1
1
E-GEOD-6400
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
heregulin
1
E-GEOD-6462
Cxcl12
1
E-GEOD-7307
NaOH
1
E-MEXP-2590
bacterial endotoxin
1
E-GEOD-3284
11 more value(s).


Biosource provider

studied in E-MTAB-37

Factor Value U/D Experiments
ECACC
1
E-MTAB-37
DSMZ
1
E-MTAB-37


BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-994, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

Disease free interval dfi in months
studied in E-GEOD-22541

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-3325, E-MEXP-2280, E-TABM-147, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-MTAB-108

Genotype
studied in E-GEOD-22056, E-TABM-321, E-TABM-601, E-MEXP-1838, E-GEOD-17347 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-MEXP-1446, E-GEOD-22278

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-GEOD-5764, E-GEOD-1926, E-MEXP-2069, E-GEOD-10433, ... (29 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-17400

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-1309, E-GEOD-1657

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1343

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-1857

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-21374

Sex
studied in E-GEOD-7307

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4271

Processing time: 0.294 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM